钠-葡萄糖协同转运蛋白2抑制剂按糖尿病状态和白蛋白尿水平的效果:一项Meta分析
该Meta分析纳入8项随机临床试验共58816名参与者,比较SGLT2抑制剂与安慰剂,按糖尿病状态和尿白蛋白肌酐比(UACR≥200 mg/g或<200 mg/g)分层。结果显示,无论有无糖尿病,SGLT2抑制剂均降低肾脏病进展、急性肾损伤、住院和死亡发生率;UACR≥200 mg/g亚组肾脏病进展的绝对获益更大,UACR<200 mg/g亚组其他疗效结局尤其是住院的绝对获益明显。
要点
- SGLT2抑制剂降低肾脏病进展风险:糖尿病者HR 0.65,非糖尿病者HR 0.74。
- UACR≥200 mg/g亚组肾脏病进展绝对获益更大,UACR<200 mg/g亚组住院绝对获益明显。
- 无论糖尿病状态和UACR水平,SGLT2抑制剂对肾脏、住院和死亡结局均有明确绝对获益。
核心结论
- 在所研究的参与者中,无论糖尿病状态和UACR水平如何,SGLT2抑制剂对肾脏、住院和死亡结局均有明确的绝对获益。
研究设计与样本
- 纳入8项随机临床试验,研究具有肾脏病适应症的SGLT2抑制剂并记录纵向肾脏结局和基线白蛋白尿数据。
- 共纳入58816名参与者,平均年龄64岁(SD 10),女性占35%,其中48946名有糖尿病,9870名无糖尿病。
- 采用逆方差加权Meta分析合并数据,通过将相对风险应用于安慰剂组事件率估计组别绝对效应。
主要发现
- 糖尿病者肾脏病进展率为33 vs 安慰剂48/1000患者年(HR 0.65,95%CI 0.60-0.70);非糖尿病者32 vs 46/1000(HR 0.74,95%CI 0.63-0.85)。
- 糖尿病者急性肾损伤率为14 vs 安慰剂18/1000(HR 0.77,95%CI 0.69-0.87);非糖尿病者13 vs 18/1000(HR 0.72,95%CI 0.56-0.92)。
- 糖尿病者任何住院率为202 vs 安慰剂231/1000(HR 0.90,95%CI 0.87-0.92);非糖尿病者203 vs 237/1000(HR 0.89,95%CI 0.83-0.95)。
- 糖尿病者任何死亡率为42 vs 安慰剂47/1000(HR 0.86,95%CI 0.80-0.91);非糖尿病者42 vs 48/1000(HR 0.91,95%CI 0.78-1.05)。
- UACR≥200 mg/g亚组肾脏病进展的估计绝对获益更大;UACR<200 mg/g亚组其他疗效结局尤其是住院的绝对获益明显。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is uncertainty about the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in participants with chronic kidney disease, with guidelines offering different strengths of recommendation based on diabetes status and urine albumin to creatinine ratio (UACR). OBJECTIVE: To assess the relative and absolute effects of SGLT2 inhibitor use across efficacy and serious safety outcomes in participants stratified by diabetes status and UACR (≥200 mg/g or <200 mg/g). DATA SOURCES AND STUDY SELECTION: Included 8 randomized clinical trials that studied an SGLT2 inhibitor with a label indication for use in kidney disease and recorded longitudinal kidney outcomes and baseline data on albuminuria. DATA EXTRACTION AND SYNTHESIS: Data were combined using inverse variance-weighted meta-analysis; group-specific absolute effects were estimated by applying relevant relative risks to the event rates of the placebo groups. MAIN OUTCOMES AND MEASURES: Assessed the effects of SGLT2 inhibitor use on clinical efficacy and safety outcomes. Heterogeneity by baseline level of UACR was assessed separately by diabetes status. RESULTS: A total of 58 816 participants (mean age, 64 [SD, 10] years; 35% were female; 48 946 with diabetes and 9870 without diabetes) were included from trials comparing an SGLT2 inhibitor vs placebo. Allocation to an SGLT2 inhibitor produced a lower rate of kidney disease progression (33 vs 48 for placebo per 1000 patient-years; hazard ratio [HR], 0.65 [95% CI, 0.60-0.70] in those with diabetes and 32 vs 46 per 1000; HR, 0.74 [95% CI, 0.63-0.85] in those without diabetes), a lower rate of acute kidney injury (14 vs 18 per 1000 [HR, 0.77; 95% CI, 0.69-0.87] with diabetes and 13 vs 18 per 1000 [HR, 0.72; 95% CI, 0.56-0.92] without diabetes), a lower rate of any hospitalization (202 vs 231 per 1000 [HR, 0.90; 95% CI, 0.87-0.92] with diabetes and 203 vs 237 per 1000 [HR, 0.89; 95% CI, 0.83-0.95] without diabetes), and a lower rate of any death (42 vs 47 per 1000 [HR, 0.86; 95% CI, 0.80-0.91] with diabetes and 42 vs 48 per 1000 [HR, 0.91; 95% CI, 0.78-1.05] without diabetes). Diabetes-specific HRs were similar in participants (with a UACR ≥200 mg/g vs with a UACR <200 mg/g) considered separately. Higher absolute risk at a UACR of 200 mg/g or greater meant larger estimated absolute benefits on kidney disease progression were evident in this subgroup. Clear absolute benefits were evident for other efficacy outcomes, and particularly hospitalization, in participants with a UACR less than 200 mg/g. Net absolute benefits remained in the analyses of non-heart failure populations and when estimated glomerular filtration rate was less than 60 mL/min/1.73 m2. CONCLUSIONS AND RELEVANCE: Within the studied participants, there were clear absolute benefits of SGLT2 inhibitors on kidney, hospitalization, and mortality outcomes irrespective of diabetes status and level of UACR.
引用
- Staplin N, Roddick AJ, Neuen BL, et al. Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis. JAMA. 2026. PMID: 41202026. doi:10.1001/jama.2025.20835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。